267 related articles for article (PubMed ID: 30661742)
1. Dedifferentiated gastrointestinal stromal tumor: Recent advances.
Karakas C; Christensen P; Baek D; Jung M; Ro JY
Ann Diagn Pathol; 2019 Apr; 39():118-124. PubMed ID: 30661742
[TBL] [Abstract][Full Text] [Related]
2. An Epithelioid Gastrointestinal Stromal Tumor of the Stomach With Strong Expression of Keratin: Clinicopathologic Correlation and Follow-up Post-Imatinib Therapy.
Baniak N; Lee L; Zhou C; Young S; Yu D
Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):e85-e90. PubMed ID: 28362703
[TBL] [Abstract][Full Text] [Related]
3. A Case of Disseminated Intra-abdominal Gastrointestinal Stromal Tumor Managed with Low Dose Imatinib.
Jang BH; Kim BW; Lim KJ; Kim BG; Park SM; Kim JS; Ji JS; Choi H
Korean J Gastroenterol; 2015 Jun; 65(6):366-9. PubMed ID: 26087692
[TBL] [Abstract][Full Text] [Related]
4. Ethyl-2-amino-pyrrole-3-carboxylates are active against imatinib-resistant gastrointestinal stromal tumors in vitro and in vivo.
Boichuk S; Galembikova A; Dunaev P; Micheeva E; Novikova M; Khromova N; Kopnin P
Anticancer Drugs; 2019 Jun; 30(5):475-484. PubMed ID: 30986804
[TBL] [Abstract][Full Text] [Related]
5. Dedifferentiated gastrointestinal stromal tumor arising de novo from the small intestine.
Choi JJ; Sinada-Bottros L; Maker AV; Weisenberg E
Pathol Res Pract; 2014 Apr; 210(4):264-6. PubMed ID: 24484970
[TBL] [Abstract][Full Text] [Related]
6. Dedifferentiation in SDH-Deficient Gastrointestinal Stromal Tumor: A Report With Histologic, Immunophenotypic, and Molecular Characterization.
Malik F; Santiago T; Bahrami A; Davis E; McCarville B; Newman S; Azzato EM; Davidoff AM; Brennan R; Ellison DW; Clay MR
Pediatr Dev Pathol; 2019 Oct; 22(5):492-498. PubMed ID: 31072206
[TBL] [Abstract][Full Text] [Related]
7. Proteogenomics for the Study of Gastrointestinal Stromal Tumors.
Kondo T
Adv Exp Med Biol; 2016; 926():139-151. PubMed ID: 27686810
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal stromal tumors (GIST): a single center experience.
Kostka R; Gürlich R; Koldová L
Acta Chir Belg; 2012 Jan; 112(1):33-9. PubMed ID: 22442907
[TBL] [Abstract][Full Text] [Related]
9. ETV1 mRNA is specifically expressed in gastrointestinal stromal tumors.
Jang BG; Lee HE; Kim WH
Virchows Arch; 2015 Oct; 467(4):393-403. PubMed ID: 26243012
[TBL] [Abstract][Full Text] [Related]
10. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB
Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855
[TBL] [Abstract][Full Text] [Related]
11. [Research advance of liquid biopsy in gastrointestinal stromal tumors].
Sun JY; Gao XD; Shen KT
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):917-921. PubMed ID: 32927519
[TBL] [Abstract][Full Text] [Related]
12. RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor.
Gao X; Xue A; Fang Y; Shu P; Ling J; Hou Y; Shen K; Qin J; Sun Y; Qin X
Oncotarget; 2016 Mar; 7(12):14300-9. PubMed ID: 26893362
[TBL] [Abstract][Full Text] [Related]
13. Cytohistological and immunohistochemical characteristics of spindle-shaped mesenchymal neoplasms occurring in the gastrointestinal tract.
Ieni A; Barresi V; Reggiani Bonetti L; Branca G; Caruso RA; Tuccari G
Scand J Gastroenterol; 2017 Mar; 52(3):291-299. PubMed ID: 27817254
[TBL] [Abstract][Full Text] [Related]
14. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.
Rausch JL; Boichuk S; Ali AA; Patil SS; Liu L; Lee DM; Brown MF; Makielski KR; Liu Y; Taguchi T; Kuan SF; Duensing A
Oncotarget; 2017 Jan; 8(3):4471-4483. PubMed ID: 27965460
[TBL] [Abstract][Full Text] [Related]
15. The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours.
Foo T; Goldstein D; Segelov E; Shapiro J; Pavlakis N; Desai J; Yip D; Zalcberg J; Price TJ; Nagrial A; Chantrill L; Burge M; Karapetis CS; Tebbutt N; Roy AC
Target Oncol; 2022 Mar; 17(2):95-110. PubMed ID: 35290591
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal stromal tumors: diagnosis and treatment.
Acín-Gándara D; Pereira-Pérez F; Castaño-Pascual A; Durán-Poveda M; Antequera-Pérez A; Miliani-Molina C
Cir Cir; 2012; 80(1):44-51. PubMed ID: 22472152
[TBL] [Abstract][Full Text] [Related]
17. DOG1 is a sensitive and specific immunohistochemical marker for diagnosis of canine gastrointestinal stromal tumors.
Dailey DD; Ehrhart EJ; Duval DL; Bass T; Powers BE
J Vet Diagn Invest; 2015 May; 27(3):268-77. PubMed ID: 25862711
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate.
Koh JS; Trent J; Chen L; El-Naggar A; Hunt K; Pollock R; Zhang W
Histol Histopathol; 2004 Apr; 19(2):565-74. PubMed ID: 15024716
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Relevance of p53 Overexpression in Gastrointestinal Stromal Tumors of the Small Intestine: Potential Implication for Adjuvant Treatment with Imatinib.
Yoo C; Koh YW; Park YS; Ryu MH; Ryoo BY; Park HJ; Yook JH; Kim BS; Kang YK
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S362-9. PubMed ID: 25791792
[TBL] [Abstract][Full Text] [Related]
20. Serum miR-518e-5p is a potential biomarker for secondary imatinib-resistant gastrointestinal stromal tumor.
Kou Y; Yang R; Wang Q
J Biosci; 2018 Dec; 43(5):1015-1023. PubMed ID: 30541960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
